Brokerages Set Nektar Therapeutics (NASDAQ:NKTR) PT at $4.08

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $4.08.

A number of brokerages have recently weighed in on NKTR. HC Wainwright restated a "buy" rating and issued a $6.50 price objective on shares of Nektar Therapeutics in a research note on Monday, January 13th. Piper Sandler started coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They set an "overweight" rating and a $7.00 target price on the stock. Finally, B. Riley started coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $4.00 target price on the stock.

Insider Buying and Selling at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 46,995 shares of the company's stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now owns 1,195,710 shares in the company, valued at $1,207,667.10. This represents a 3.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Zalevsky sold 51,115 shares of the company's stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the transaction, the insider now owns 326,904 shares in the company, valued at approximately $307,289.76. This trade represents a 13.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 155,575 shares of company stock valued at $149,878 in the last 90 days. 3.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NKTR. Valence8 US LP acquired a new position in Nektar Therapeutics during the 3rd quarter valued at about $34,000. Intech Investment Management LLC acquired a new position in Nektar Therapeutics during the 3rd quarter valued at about $41,000. XTX Topco Ltd acquired a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $46,000. Moloney Securities Asset Management LLC raised its position in shares of Nektar Therapeutics by 42.4% in the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $46,000 after acquiring an additional 14,895 shares during the period. Finally, HB Wealth Management LLC raised its position in shares of Nektar Therapeutics by 44.0% in the 4th quarter. HB Wealth Management LLC now owns 64,100 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 19,600 shares during the period. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Nektar Therapeutics Trading Down 5.3 %

NASDAQ NKTR traded down $0.04 during trading on Friday, reaching $0.66. The company's stock had a trading volume of 4,154,963 shares, compared to its average volume of 1,964,966. The business has a 50-day moving average price of $0.93 and a 200-day moving average price of $1.14. Nektar Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.93. The stock has a market capitalization of $122.33 million, a PE ratio of -0.79 and a beta of 0.58.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.